Skip to content

Starting HIV treatment reduces risk of death from all causes; additional benefits if treatment started sooner

Full results of DART lab monitoring study published

US guidelines now favour treatment at CD4 cell counts between 350 and 500; above 500 not ruled out

WHO recommends earlier treatment and phase-out of d4T

Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?

New EACS guidelines address co-morbidities and diseases of age

Cost-effective ways to reduce loss to follow-up in ART programmes identified

FDA committee recommends approval of maraviroc for first-line treatment in US

CD4 cell count below 500 increases cancer risk for patients with HIV